Solorank
Login

Cached score snapshot

US.VRTX · Vertex Pharmaceuticals

110分制 58/110；5D動能v2 7/50；排序分 65/160

Back to ranking Open volume snapshot
Ranking score 65/160
Main score 58/110
5D momentum v2 7/50
Rank #260
Setup grade F 33.2

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 33.2 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 08-04 09-16 10-28 11-18 12-08 $456.22$523.57$590.92 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling calibration best · score 2.507 · anchors 120 +1.62% -1.05% / +3.71% 70% 2.5% Actual outcome pending · 0 / 3 bars observed
30D observation +1.59% -2.65% / +9.13% 55% 17.5% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 +1.35% -1.11% / +3.10% 67.5% 2.5% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-08-04 → 2026-12-08 · 120 archived points · 1 Improving turn signal · 6 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 65
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 58/110 (觀望)
5D momentum v2 7/50 (弱)
Score with momentum v2 65/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 509.8505
ma50 523.0532
close 521.03
prevClose 517.49
avgVolume20 1265506
volumeRatio 0.81
changePercent 0.68

Metrics snapshot

close 521.03
volume 1019510
changePercent 0.68

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 58/110
Main rating 觀望
5D momentum v2 7/50
Score with momentum v2 65/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.8/5 · 良好
Dimension score 3.8/5
Dimension grade 良好

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 531.1953
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 13.2/20 · 一般
Dimension score 13.2/20
Dimension grade 一般

Sub-items

cmfPoints 0.8
mfiPoints 2.4
obvPoints 4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.VRTX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 9.8/15 · 一般
Dimension score 9.8/15
Dimension grade 一般

Sub-items

vix

score 1.8

details

source twelvedata+fred
vixClose 18.39

trend

score 1.8

details

qqq

ma20 733.184
ma50 725.2622
name QQQ
close 721.24
points 0.4

spy

ma20 770.4115
ma50 767.5288
name SPY
close 769.66
points 1.4
source twelvedata+fred
atrPct 2.8276
atrPoints 3
cciPoints 3.2
vixPoints 1.8
marketTrendPoints 1.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 6.8/10 · 一般
Dimension score 6.8/10
Dimension grade 一般

Sub-items

position

score 1.6

details

atrPct 2.8276
turnoverUsdM 531.1953
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 491.565

strength_details

ma_score 1
atr_score 2
rsi_score 2
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 5.7
take_profit_price 555.5532
target_multiplier 1.9
technical_strength 1.85
take_profit_percent 6.6
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.6551
diversificationPoints 2

技術信號 — 18.4/30 · 一般
Dimension score 18.4/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.9
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 0.9
vcp_reason 靠近20日高位；升放量(近10日6日)；Ready=N；Confirm=Y

vcp_metrics

up_days 6
vol_ref 1193410
down_days 3
vcp_ready false
above_ma50 false
avg_vol_10 1459260
avg_vol_20 1248970
avg_vol_30 1193410
range_pct_10 0.1031
range_pct_20 0.1031
range_pct_30 0.1031
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok false
up_expand_days 6
breakout_20d_ok false
vol_ratio_10_30 1.2228
dist_to_20d_high 0.0312
down_shrink_days 2
breakout_level_20d 537.81
vcp_breakout_confirm true
contraction_ratio_10_30 1
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 0
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":143204127,"url":"https://finnhub.io/api/news?id=258a4bb0d11945da722a9ae678431bdc0478cda5414a4d4cb72fbd2744f0a9d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.","category":"company","datetime":1793047803,"headline":"Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why"}, {"id":143199226,"url":"https://finnhub.io/api/news?id=bdf18ee067ea52c5f3bd1f611b3a76971489aa2dbbfa8270d566be8aa6a65fc8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1793019606,"headline":"Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"}, {"id":143171535,"url":"https://finnhub.io/api/news?id=72611d4e3692d189523d697231759b17d5cc53fac517569bd6c4b8364a3727b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...","category":"company","datetime":1792898396,"headline":"Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept"}, {"id":143150593,"url":"https://finnhub.io/api/news?id=673707359a4a72492df4a07e6cbf617ad61018a54cf7407743e17065b1091244","image":"","source":"SeekingAlpha","related":"VRTX","summary":"","category":"company","datetime":1792812435,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript"}, {"id":143141725,"url":"https://finnhub.io/api/news?id=cf10aef4f3779a6f6eab5faf759d7610b698c4dc8a702bd883b061875ee7367a","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.","category":"company","datetime":1792791065,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow"}, {"id":143104142,"url":"https://finnhub.io/api/news?id=8be9cda696951d7b2fa53e3f1851c49e66e1ca650ebc8694dae5425b54a4573d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]","category":"company","datetime":1792701202,"headline":"Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?"}, {"id":143033121,"url":"https://finnhub.io/api/news?id=59314c7ab71cb22d75b313016495700c4c5d175bb0a4e388ad53dbc7407cf9d2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.","category":"company","datetime":1792529403,"headline":"Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know"}, {"id":142987498,"url":"https://finnhub.io/api/news?id=31fdc9f85d46544de5546224dd35c3aade7953f6ed84d54221601ad790c35dab","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...","category":"company","datetime":1792336361,"headline":"What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders"}
raw_source {"id":143239487,"url":"https://finnhub.io/api/news?id=be2e3b21fd9eb83f339c1110580ecb3dd939370f9061276111c233345caa6506","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.","category":"company","datetime":1793130302,"headline":"Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue"}, {"id":143237044,"url":"https://finnhub.io/api/news?id=70e62b90da2305d915aaeaffadc77c94587c3ff55459331078ba1baa93e20e3a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.","category":"company","datetime":1793110500,"headline":"Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?"}, {"id":143234382,"url":"https://finnhub.io/api/news?id=ec7e39c6c4ea26add9e2e2c26a84f149da9e9de859dd8aad122a504ad06f0c21","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Investing.com -- BofA Securities kept this drugmaker a “top pick” and reiterated its “buy” rating and $667 price objective after the company presented new kidney drug data at the American Society of Nephrology meeting.","category":"company","datetime":1793106545,"headline":"BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data"}, {"id":143204127,"url":"https://finnhub.io/api/news?id=258a4bb0d11945da722a9ae678431bdc0478cda5414a4d4cb72fbd2744f0a9d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.","category":"company","datetime":1793047803,"headline":"Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why"}, {"id":143202708,"url":"https://finnhub.io/api/news?id=4e46a0e6db0ca66685a362dfc0a8fde4e37b264e110896e42a90a4e16de6c6a2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.","category":"company","datetime":1793035980,"headline":"BHC Q3 Earnings Preview: Here's What You Should Know"}, {"id":143198057,"url":"https://finnhub.io/api/news?id=d531d68b8d8bcb90235142450233bc793a628c4634ceaf8cac6c4cfb681acb07","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]","category":"company","datetime":1793022342,"headline":"The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2"}, {"id":143199226,"url":"https://finnhub.io/api/news?id=bdf18ee067ea52c5f3bd1f611b3a76971489aa2dbbfa8270d566be8aa6a65fc8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1793019606,"headline":"Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"}, {"id":143191625,"url":"https://finnhub.io/api/news?id=f488331be4fc0aabb6b91d631958c54c2e6eedde32af3d9e4b889a6a1c65305b","image":"","source":"SeekingAlpha","related":"VRTX","summary":"","category":"company","datetime":1792987500,"headline":"Baron Health Care Fund: Q3 2026 New Positions And Exits"}, {"id":143171535,"url":"https://finnhub.io/api/news?id=72611d4e3692d189523d697231759b17d5cc53fac517569bd6c4b8364a3727b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...","category":"company","datetime":1792898396,"headline":"Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept"}, {"id":143171536,"url":"https://finnhub.io/api/news?id=11495983ee2e783219b158fca8e139e869775142665cd044d8f4e01226dea782","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...","category":"company","datetime":1792894196,"headline":"What Vertex Pharmaceuticals Holders Bought Into"}, {"id":143168755,"url":"https://finnhub.io/api/news?id=4eaf0acb3316447083c94261a89a31b2ccf18e13aba019c2cc4b936fea495114","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The company's gene-editing-focused platform looks promising.","category":"company","datetime":1792880400,"headline":"Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More"}, {"id":143166876,"url":"https://finnhub.io/api/news?id=3c135b6892c7278f17f00d80171c8d2c80252353cd0eb810b470ac44c2016740","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex is expanding beyond its cystic fibrosis franchise.","category":"company","datetime":1792870140,"headline":"Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change."}, {"id":143150593,"url":"https://finnhub.io/api/news?id=673707359a4a72492df4a07e6cbf617ad61018a54cf7407743e17065b1091244","image":"","source":"SeekingAlpha","related":"VRTX","summary":"","category":"company","datetime":1792812435,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript"}, {"id":143144085,"url":"https://finnhub.io/api/news?id=dded9140786f404630f7bf6e3ca4e57335a90cae80dfc4563ead4f419d6eb3cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm","category":"company","datetime":1792810923,"headline":"Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III"}, {"id":143141725,"url":"https://finnhub.io/api/news?id=cf10aef4f3779a6f6eab5faf759d7610b698c4dc8a702bd883b061875ee7367a","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.","category":"company","datetime":1792791065,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow"}, {"id":143137021,"url":"https://finnhub.io/api/news?id=ee9914d7c012c3940106e13b79be6b379e8b83bc1f66908de6edc2f5b0d147e7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots","category":"company","datetime":1792786277,"headline":"How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs"}, {"id":143136366,"url":"https://finnhub.io/api/news?id=31de2771bdcfe4c0b02349b053147edc97577ab991ed2c57d4219a9567ec6285","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, October 23, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a","category":"company","datetime":1792777320,"headline":"Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026"}, {"id":143136365,"url":"https://finnhub.io/api/news?id=4096afeeab360911f0fd6be6f61127974edc9434f479a10014bbe6db6d27b373","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"For questions about this article or underlying research, email help@trefis.com.","category":"company","datetime":1792776565,"headline":"Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?"}, {"id":143164024,"url":"https://finnhub.io/api/news?id=7bf434c0ccbe5ba3d62b42e7e47d658d82d5e63122da079c85b6b4b5d46e4aaf","image":"","source":"Benzinga","related":"VRTX","summary":"- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s","category":"company","datetime":1792762993,"headline":"Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30"}, {"id":143133547,"url":"https://finnhub.io/api/news?id=772806fd053104a668901b32faf54bf45e0835695b33e1dc35a9d3f2fbeb914e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots","category":"company","datetime":1792756851,"headline":"How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs"}, {"id":143104142,"url":"https://finnhub.io/api/news?id=8be9cda696951d7b2fa53e3f1851c49e66e1ca650ebc8694dae5425b54a4573d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]","category":"company","datetime":1792701202,"headline":"Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?"}, {"id":143135359,"url":"https://finnhub.io/api/news?id=9d437d1f1011e9c7cce6e66eee3cca9850bf5b5369d42816d8af6b0029d75621","image":"","source":"Benzinga","related":"VRTX","summary":"www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1154326","category":"company","datetime":1792671246,"headline":"Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s Syndrome"}, {"id":143099227,"url":"https://finnhub.io/api/news?id=2ebfb5c5ececa35f9094799bf56c6c968630fe538d74ccf06c335b846e64f665","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profilesVANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has secured the approvals, permits and land access permissions required to commence its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and L","category":"company","datetime":1792670400,"headline":"Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project"}, {"id":143070139,"url":"https://finnhub.io/api/news?id=fd0f9110765fd8e5d5482f6bab2529f4661cb2a3525b1f8acb4178d99bca0210","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]","category":"company","datetime":1792595942,"headline":"Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?"}, {"id":143087262,"url":"https://finnhub.io/api/news?id=eba9a293516889b9db11cf3881c5665bd9e741fb9e36f87cf455c1d1c54b430a","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"VRTX","summary":"S&P 500 premarket movers on Oct. 21: SMCI, DELL, VRT, LITE, BE and HPE led gainers, while ISRG, NFLX, T, ABT and DHR led declines.","category":"company","datetime":1792586166,"headline":"S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines"}, {"id":143036037,"url":"https://finnhub.io/api/news?id=30f63c6b342f081d573a977ff03988b6c8ab2d7237b1dd6dd44ca651ef06d703","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time","category":"company","datetime":1792544172,"headline":"Why Should You Think About Vertex Differently Now?"}, {"id":143032156,"url":"https://finnhub.io/api/news?id=e49558c555026b92434592fdc119c2a0057ebb415679b659eb4a3f1b8bd61926","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.","category":"company","datetime":1792532102,"headline":"AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"}, {"id":143033121,"url":"https://finnhub.io/api/news?id=59314c7ab71cb22d75b313016495700c4c5d175bb0a4e388ad53dbc7407cf9d2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.","category":"company","datetime":1792529403,"headline":"Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know"}, {"id":143032238,"url":"https://finnhub.io/api/news?id=06f6faed4bd65e9c0e32c1aeac93309d2b2c65babcc52e7ea6d47576de38a794","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, October 20, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Fi","category":"company","datetime":1792526700,"headline":"Vertex Appoints Daniel Brennan to its Board of Directors"}, {"id":142987498,"url":"https://finnhub.io/api/news?id=31fdc9f85d46544de5546224dd35c3aade7953f6ed84d54221601ad790c35dab","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...","category":"company","datetime":1792336361,"headline":"What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders"}, {"id":142986224,"url":"https://finnhub.io/api/news?id=a17342c01986484a9cb93f40b6ab82d2decc2b5b16eba0c7b3ecd4fe51a86222","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.","category":"company","datetime":1792321800,"headline":"Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock."}, {"id":142964351,"url":"https://finnhub.io/api/news?id=ca7f8d158feb573ae50822814442690e4de3a51cacbb99511721b68fe77fa342","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals has rewarded long term shareholders, and that kind of track record naturally raises the question of whether today's valuation is still grounded in the cash the business can produce. With fresh data on its cystic fibrosis pipeline and gene therapy progress in the spotlight, investors are increasingly asking how much of that story is already priced into Vertex's cash flows. Over the past 5 years, Vertex has delivered a share price gain of 172.3%. That puts a lot of...","category":"company","datetime":1792278652,"headline":"Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data"}, {"id":142963250,"url":"https://finnhub.io/api/news?id=d458f85fe45cebc4fcb8879f931134b5c1576acb47bc906b063a31c95c7dc32f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) stepped into the spotlight after new interim ALYFTREK data at the North American Cystic Fibrosis Conference suggested some young children regained pancreatic function and were able to stop enzyme replacement therapy. For context, Vertex Pharmaceuticals has given investors a mixed near term ride, with the 1 day share price return down 1.77% and the 30 day share price return down 2.63%, yet the 90 day share price return up 2.90% and the year to date share price...","category":"company","datetime":1792264486,"headline":"Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In Focus"}, {"id":142945741,"url":"https://finnhub.io/api/news?id=aa2105c9129f5b1e79dd93448f96bf7795534765edd2ca26e7931a7d7caa68b0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.","category":"company","datetime":1792152004,"headline":"Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?"}, {"id":142944344,"url":"https://finnhub.io/api/news?id=eae8138802e1a47950740af6353ed57068f6be231a03953b3a9fa4398093b93c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.","category":"company","datetime":1792149819,"headline":"1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm"}, {"id":142948842,"url":"https://finnhub.io/api/news?id=bcb654cc305cf790e80039297d36eecf57a6a4a488bec6137e1fe7fd7a648857","image":"https://image.cnbcfm.com/api/v1/image/108415090-1792083266137-107344708-1701972953198-AP23320388297314.webp?v=1792083320&w=1920&h=1080","source":"CNBC","related":"VRTX","summary":"FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.","category":"company","datetime":1792142349,"headline":"Sickle cell gene therapies offer new hope, but access remains a major challenge"}, {"id":142923087,"url":"https://finnhub.io/api/news?id=6e35fd378e0a62ce6cc88378c605bbccbc99f8b9337b10d9e7bf2453c4481ca8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.","category":"company","datetime":1792098006,"headline":"Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts"}, {"id":142922371,"url":"https://finnhub.io/api/news?id=0e48348bc22a684c8a5a23abf82aeaab9b4850204e500088437e94878636b06e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release on July 24, 2026, that it has extended its engagement of MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 45 days, commencing Oct 19, 2026, provided that the term of the ma","category":"company","datetime":1792098000,"headline":"Vortex Energy Corp. Announces Extension of Marketing Program"}, {"id":142919154,"url":"https://finnhub.io/api/news?id=553e59ad7b882c48cf23a174969915e627a5fd8d536b75959bd925986da895c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals is showing that it isn't a one-trick pony.","category":"company","datetime":1792076460,"headline":"Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders"}, {"id":142921489,"url":"https://finnhub.io/api/news?id=37d2bd83656f0939b72efc73b6be3ef5abdffb99ba08e5f7de62fc4afbee0396","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals is set to report its Q3 results next month, with analysts anticipating single-digit EPS growth alongside continued earnings growth.","category":"company","datetime":1792068252,"headline":"What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release"}, {"id":142881738,"url":"https://finnhub.io/api/news?id=72e7c9e44734b50cdef94c88faa680defd3c10cc3071502c03fa5b38fac7847a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Rising gasoline and diesel costs are pushing US inflation higher, and that puts steady cash generation and conservative balance sheets back in the spotlight. When borrowing stays expensive and prices keep climbing, investors often pay closer attention to companies that already throw off cash and carry less debt. This article breaks down three such undervalued high quality stocks and explains why they might deserve a spot on your watchlist now. The stocks highlighted below are just a small...","category":"company","datetime":1791976283,"headline":"3 Top Quality Value Stocks To Watch In October 2026"}, {"id":142848728,"url":"https://finnhub.io/api/news?id=4ff718c0d17dfa447f9637b4c4aecc5e4e89c933ebad91449ca247f2ad041a9e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.","category":"company","datetime":1791895025,"headline":"Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"}, {"id":142819167,"url":"https://finnhub.io/api/news?id=9202fe518a488cc7029f2456af0fc3ba7be6c9d583a9d1306d3305f451800fcb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.","category":"company","datetime":1791801063,"headline":"2 High-Flying Stocks on Our Watchlist and 1 We Question"}, {"id":142767990,"url":"https://finnhub.io/api/news?id=c23fb25d8e354123601b2e2720c3044259dca98eec6080b2d7c03a9f5980203d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.","category":"company","datetime":1791579003,"headline":"Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know"}, {"id":142765367,"url":"https://finnhub.io/api/news?id=992912428f38dc107073c12c6a342e476503b1ef0a2f1fdff7eb3e860085c08d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib","category":"company","datetime":1791566100,"headline":"Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference"}, {"id":142764205,"url":"https://finnhub.io/api/news?id=78f2a1b20a92c2f2664cbf93a4df03d907ffde640be59eabf97e4f652329c59c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.","category":"company","datetime":1791560209,"headline":"Is Vertex Stock Worth More Than Its Competitors?"}, {"id":142791249,"url":"https://finnhub.io/api/news?id=ce130766d00aa1c08d2a1df20fc7bd34f115e6fe5d4865d156ff6c101c615623","image":"","source":"Benzinga","related":"VRTX","summary":"- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented -Vertex","category":"company","datetime":1791551850,"headline":"Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis"}, {"id":142791250,"url":"https://finnhub.io/api/news?id=3d3e37c3f06a870cbec31c0f6d53233afd5f5565019bba624ae01b7aa75b6011","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a market","category":"company","datetime":1791541816,"headline":"If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today"}, {"id":142764929,"url":"https://finnhub.io/api/news?id=be680a565332fc5f7ae8ac268fd4c925ad8cd9d4784cc24b509d7d120a2a1540","image":"https://image.cnbcfm.com/api/v1/image/108376811-1791466603254-f527cd41-e1f4-4eb3-9865-63a2ba75f085.jpg?v=1791466673&w=1920&h=1080","source":"CNBC","related":"VRTX","summary":"For the final 10% of cystic fibrosis patients who cannot benefit from breakthrough drugs, Emily's Entourage is funding research to find treatments.","category":"company","datetime":1791529201,"headline":"For the final 10% of cystic fibrosis patients, the breakthrough still hasn't come"}, {"id":142730997,"url":"https://finnhub.io/api/news?id=432e0925ebab3aeb2ff78568017b127382217a73fb75460d7f75b5111e5a2c09","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications.","category":"company","datetime":1791480540,"headline":"Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition"}, {"id":142729942,"url":"https://finnhub.io/api/news?id=e6f46e10b531fadf9511813c96e130f8dcb6ef08c2be2d1a0d6dc481a193f9a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher interest rates, and persistent inflation created headwinds for equities and bonds, although strong corporate earnings and continued AI investment helped support […]","category":"company","datetime":1791467998,"headline":"Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why"}, {"id":142762432,"url":"https://finnhub.io/api/news?id=cb41862f1e2653e356536ac1c78b5786d53ca2c35c8a4c0ba89ccceab1a9f0fb","image":"","source":"Benzinga","related":"VRTX","summary":"RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.","category":"company","datetime":1791454303,"headline":"RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576"}, {"id":142700467,"url":"https://finnhub.io/api/news?id=171419e8f3d4371fa9aeba7aff9191a02d227a86a40539d8b98c67c7d01a1ee7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, October 07, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.\"","category":"company","datetime":1791403200,"headline":"Vertex to Announce Third Quarter 2026 Financial Results November 2nd"}, {"id":142688595,"url":"https://finnhub.io/api/news?id=850cee1d2d2199d33e784edd409b737c35f19becfe776b1cac3049376df916ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and still trade as if they are largely overlooked. This article breaks down three such high quality but ignored US stocks from our screener and explains why they may warrant a closer look. The three stocks covered below are just a starting sample, since the full...","category":"company","datetime":1791365064,"headline":"NVIDIA And 2 Elite Undervalued Stocks To Own"}, {"id":142652471,"url":"https://finnhub.io/api/news?id=64e8feaa5bebd866362af05857dd3615e6f456997b2380633ef07012abc6d3a2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.","category":"company","datetime":1791267180,"headline":"Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?"}, {"id":142662618,"url":"https://finnhub.io/api/news?id=d78ffd39021735e4739cfbbd4e7ce2c89bcdbad94ff4f003fc44637d8d221831","image":"https://cdn.benzinga.com/files/images/story/2026/10/05/Nasdaq-Inscription-Next-To-Us-Dollars--T.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.","category":"company","datetime":1791212429,"headline":"Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average"}, {"id":142635190,"url":"https://finnhub.io/api/news?id=1796d84c2e8a9f60a1a7b9d29266b5788128dd7ef6544af57255d46a92509159","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1791201607,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know"}, {"id":142635191,"url":"https://finnhub.io/api/news?id=943cb8c1f83470d9cc644feb430e61cb7adee87a478c61044c0106a7f544aae2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potentialVANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons Ri","category":"company","datetime":1791201600,"headline":"Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project"}, {"id":142632186,"url":"https://finnhub.io/api/news?id=e577f7a9f57d44c3b91d86f0a9d89c225339a9fd4ab39a07dabc04048da37e08","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.","category":"company","datetime":1791194100,"headline":"2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down"}, {"id":142624185,"url":"https://finnhub.io/api/news?id=773d3787e684fba498bba3b49094c209329c0e46fcca5973e7c495eb6d0c1b89","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.","category":"company","datetime":1791124497,"headline":"Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"}, {"id":142600044,"url":"https://finnhub.io/api/news?id=1510dab33932c078bbdfa82bd31981132c1fe6efe647aba58030c1ffd02f120c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]","category":"company","datetime":1790995209,"headline":"Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets"}, {"id":142563799,"url":"https://finnhub.io/api/news?id=33db27cdedbadf5d64a8a23a56996eefb15a99869c55975888b7930bc6d25e12","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...","category":"company","datetime":1790892442,"headline":"Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks"}, {"id":142563800,"url":"https://finnhub.io/api/news?id=f4e27e824ed2216180d2fc1ff43a6009ba5e9ba7b333adb15c9fd852d617ac38","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.","category":"company","datetime":1790888406,"headline":"Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know"}, {"id":142562962,"url":"https://finnhub.io/api/news?id=8b2cc6a116d127762d8c7ff932bc5889f16d9ceca2d269093a071a3cf8886285","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (\"Vortex\" or the \"Company\") is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the \"Meadows Project\"). The Meadows Project is represented by Saskatchewan Subsur","category":"company","datetime":1790888400,"headline":"Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan"}, {"id":142562009,"url":"https://finnhub.io/api/news?id=efdd7ae1fb5005fdb07db2a037384ba09bae20b4b50dc26ed3c05ad7df9cd2ef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.","category":"company","datetime":1790882255,"headline":"Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"}, {"id":142540765,"url":"https://finnhub.io/api/news?id=7d6465b472d118677c03014527a5f47cd568772afebdfde05f26b16e70df37cb","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440523601/image_1440523601.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.","category":"company","datetime":1790825460,"headline":"The Top HealthTech Questions Landing On Our Desks"}, {"id":142520017,"url":"https://finnhub.io/api/news?id=645e00c63c078d5113e0f74e41cc2998e00ddd331b98c15a9aba17eb591b050c","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market","category":"company","datetime":1790698533,"headline":"$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today"}, {"id":142517094,"url":"https://finnhub.io/api/news?id=cb1f42ba0619a23b4870af3deeed19596359754d26553e137f4f5b0e7ce4a583","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will","category":"company","datetime":1790688914,"headline":"10 Health Care Stocks Whale Activity In Today’s Session"}, {"id":142488937,"url":"https://finnhub.io/api/news?id=77a4693c64636b6f902d7874bb26412235939b809c4b9d7c878e6e5d6afd88e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"This biotech player is firing on all cylinders.","category":"company","datetime":1790674200,"headline":"2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right."}, {"id":142495235,"url":"https://finnhub.io/api/news?id=159fbb2c029dd797d2b9e77c1bf78c3fe5e3de6e5840d79f57d72604817f8792","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/178368474/image_178368474.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Vertex Pharmaceuticals commands a dominant, highly profitable cystic fibrosis franchise. Find out why VRTX stock is downgraded to a hold.","category":"company","datetime":1790670621,"headline":"Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade"}, {"id":142493778,"url":"https://finnhub.io/api/news?id=0b2f7f810f70395a2cacb2e0d08118903ac1ac743984c1905bf6998b3ab15787","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237482641/image_2237482641.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.","category":"company","datetime":1790667020,"headline":"Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress"}, {"id":142474021,"url":"https://finnhub.io/api/news?id=53f4be2f0dd2ed26d97af2ff1e281be817a054b406c7bd3b609affe35a6362ec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]","category":"company","datetime":1790642228,"headline":"Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?"}, {"id":142495491,"url":"https://finnhub.io/api/news?id=93f4cbe113b07d716821f1fd4548930b4da186454498b35f96b848e003e63541","image":"https://cdn.benzinga.com/files/images/story/2026/09/28/Grid-Delays-Stall-Data-Centers.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.","category":"company","datetime":1790606813,"headline":"Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday"}, {"id":142496737,"url":"https://finnhub.io/api/news?id=2d4021a8657172a482a3f220c240c24bbceff45d44e7e6f1f0f12be23a652488","image":"","source":"Benzinga","related":"VRTX","summary":"UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.","category":"company","datetime":1790604049,"headline":"UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615"}, {"id":142463805,"url":"https://finnhub.io/api/news?id=755d2c372c9a61d3c7e7d4171d959a6953d7d8fb9e6d1302ea12d1028db6c15a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 46.9% over the past six months, topping the S&P 500 by 25.5 percentage points.","category":"company","datetime":1790591916,"headline":"2 Healthcare Stocks to Target This Week and 1 We Avoid"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 75
discarded_article_count 57
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.8 5/110 76% 3.8
資金流 13.2 20/110 66% 13.2
市場環境 9.8 15/110 65.33% 9.8
催化劑 2 20/110 10% 2
風險管理 6.8 10/110 68% 6.8
技術信號 18.4 30/110 61.33% 18.4
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 7/50
ret_5d 0.0124
max_score 50
max_total 50
raw_total 7
vcp_bonus 0
vol_ratio 0.8163
ret_points 4
vol_points 0
range_ratio 0.9508
volat_points 0
day_range_pct 0.0235
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.8276
turnoverUsdM 531.1953
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 491.565

strength_details

ma_score 1
atr_score 2
rsi_score 2
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 5.7
take_profit_price 555.5532
target_multiplier 1.9
technical_strength 1.85
take_profit_percent 6.6
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.6551
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.8/5分
資金流分析總分: 13.2/20分
市場環境分析總分: 9.8/15分
催化劑分析: 2/20分
風險管理總分: 6.8/10分
技術信號分析總分: 18.4/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 71.43
atr
atr 14.7325
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.83
cci
rule Cursor_18.24 CCI bands
level 適中偏強
score 8
value 55.8
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.1021
kdj
d 68.86
j 64.09
k 67.27
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 57.07
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 11326010
recentSlope 546591
previousSlope -307480
rsi
value 56.24
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 495.1657
position SAR喺價下
distancePct 4.96
previousTrend 上升
ma50
value 523.0532
macd
macd 1.3413
trend 強烈看漲
signal -1.2893
histogram 2.6306
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 510.2285
position 連續5日>VWAP
consecutiveAbove 6
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.81
score 4
avgVolume 1265506
currentVolume 1019510
derived
ma20 509.8505
ma50 523.0532
prevClose 517.49
avgVolume10 1442481
avgVolume20 1265506
changePercent 0.68
avgVolumeForScore 1265506
ma_cross
ma20 509.8505
ma50 523.0532
rule Cursor_18.24 MA20/MA50 cross
cross 熊勢
score 0
prevMa20 510.1355
prevMa50 522.9436
spreadPct 2.52
isVolumeBreakout false
bollinger
lower 487.3439
upper 532.3571
position 上半部
rsi_short
value 67.52
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.81

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.8275721513164456,
        "turnoverUsdM": 531.19532486579,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 491.565,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.7,
      "take_profit_price": 555.5532,
      "target_multiplier": 1.9,
      "technical_strength": 1.85,
      "take_profit_percent": 6.6
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.655144302632891,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 509.8505,
    "ma50": 523.0532,
    "close": 521.03,
    "prevClose": 517.49,
    "avgVolume20": 1265506,
    "volumeRatio": 0.81,
    "changePercent": 0.68
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.012396791512803151,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.8162806152269471,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.950788991257386,
      "volat_points": 0,
      "day_range_pct": 0.023463139012281316,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 9.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 65.33,
        "contribution": 9.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 18.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 61.33,
        "contribution": 18.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 58,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 9.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 18.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 13.2,
      "市場環境": 9.8,
      "情緒分析": 4,
      "技術信號": 18.4,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 531.19532486579,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.39
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 733.18400235,
                "ma50": 725.2621992000002,
                "name": "QQQ",
                "close": 721.23999,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.4114959000001,
                "ma50": 767.5287948999999,
                "name": "SPY",
                "close": 769.65997,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.8275721513164456,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 1.8,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143204127,
                "url": "https://finnhub.io/api/news?id=258a4bb0d11945da722a9ae678431bdc0478cda5414a4d4cb72fbd2744f0a9d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.",
                "category": "company",
                "datetime": 1793047803,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 143199226,
                "url": "https://finnhub.io/api/news?id=bdf18ee067ea52c5f3bd1f611b3a76971489aa2dbbfa8270d566be8aa6a65fc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1793019606,
                "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 143171535,
                "url": "https://finnhub.io/api/news?id=72611d4e3692d189523d697231759b17d5cc53fac517569bd6c4b8364a3727b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...",
                "category": "company",
                "datetime": 1792898396,
                "headline": "Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept"
              },
              {
                "id": 143150593,
                "url": "https://finnhub.io/api/news?id=673707359a4a72492df4a07e6cbf617ad61018a54cf7407743e17065b1091244",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1792812435,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript"
              },
              {
                "id": 143141725,
                "url": "https://finnhub.io/api/news?id=cf10aef4f3779a6f6eab5faf759d7610b698c4dc8a702bd883b061875ee7367a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.",
                "category": "company",
                "datetime": 1792791065,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow"
              },
              {
                "id": 143104142,
                "url": "https://finnhub.io/api/news?id=8be9cda696951d7b2fa53e3f1851c49e66e1ca650ebc8694dae5425b54a4573d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]",
                "category": "company",
                "datetime": 1792701202,
                "headline": "Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?"
              },
              {
                "id": 143033121,
                "url": "https://finnhub.io/api/news?id=59314c7ab71cb22d75b313016495700c4c5d175bb0a4e388ad53dbc7407cf9d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.",
                "category": "company",
                "datetime": 1792529403,
                "headline": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know"
              },
              {
                "id": 142987498,
                "url": "https://finnhub.io/api/news?id=31fdc9f85d46544de5546224dd35c3aade7953f6ed84d54221601ad790c35dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...",
                "category": "company",
                "datetime": 1792336361,
                "headline": "What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders"
              }
            ],
            "raw_source": [
              {
                "id": 143239487,
                "url": "https://finnhub.io/api/news?id=be2e3b21fd9eb83f339c1110580ecb3dd939370f9061276111c233345caa6506",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.",
                "category": "company",
                "datetime": 1793130302,
                "headline": "Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue"
              },
              {
                "id": 143237044,
                "url": "https://finnhub.io/api/news?id=70e62b90da2305d915aaeaffadc77c94587c3ff55459331078ba1baa93e20e3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.",
                "category": "company",
                "datetime": 1793110500,
                "headline": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?"
              },
              {
                "id": 143234382,
                "url": "https://finnhub.io/api/news?id=ec7e39c6c4ea26add9e2e2c26a84f149da9e9de859dd8aad122a504ad06f0c21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Investing.com -- BofA Securities kept this drugmaker a “top pick” and reiterated its “buy” rating and $667 price objective after the company presented new kidney drug data at the American Society of Nephrology meeting.",
                "category": "company",
                "datetime": 1793106545,
                "headline": "BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data"
              },
              {
                "id": 143204127,
                "url": "https://finnhub.io/api/news?id=258a4bb0d11945da722a9ae678431bdc0478cda5414a4d4cb72fbd2744f0a9d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.",
                "category": "company",
                "datetime": 1793047803,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 143202708,
                "url": "https://finnhub.io/api/news?id=4e46a0e6db0ca66685a362dfc0a8fde4e37b264e110896e42a90a4e16de6c6a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.",
                "category": "company",
                "datetime": 1793035980,
                "headline": "BHC Q3 Earnings Preview: Here's What You Should Know"
              },
              {
                "id": 143198057,
                "url": "https://finnhub.io/api/news?id=d531d68b8d8bcb90235142450233bc793a628c4634ceaf8cac6c4cfb681acb07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]",
                "category": "company",
                "datetime": 1793022342,
                "headline": "The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2"
              },
              {
                "id": 143199226,
                "url": "https://finnhub.io/api/news?id=bdf18ee067ea52c5f3bd1f611b3a76971489aa2dbbfa8270d566be8aa6a65fc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1793019606,
                "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 143191625,
                "url": "https://finnhub.io/api/news?id=f488331be4fc0aabb6b91d631958c54c2e6eedde32af3d9e4b889a6a1c65305b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1792987500,
                "headline": "Baron Health Care Fund: Q3 2026 New Positions And Exits"
              },
              {
                "id": 143171535,
                "url": "https://finnhub.io/api/news?id=72611d4e3692d189523d697231759b17d5cc53fac517569bd6c4b8364a3727b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...",
                "category": "company",
                "datetime": 1792898396,
                "headline": "Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept"
              },
              {
                "id": 143171536,
                "url": "https://finnhub.io/api/news?id=11495983ee2e783219b158fca8e139e869775142665cd044d8f4e01226dea782",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...",
                "category": "company",
                "datetime": 1792894196,
                "headline": "What Vertex Pharmaceuticals Holders Bought Into"
              },
              {
                "id": 143168755,
                "url": "https://finnhub.io/api/news?id=4eaf0acb3316447083c94261a89a31b2ccf18e13aba019c2cc4b936fea495114",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The company's gene-editing-focused platform looks promising.",
                "category": "company",
                "datetime": 1792880400,
                "headline": "Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More"
              },
              {
                "id": 143166876,
                "url": "https://finnhub.io/api/news?id=3c135b6892c7278f17f00d80171c8d2c80252353cd0eb810b470ac44c2016740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex is expanding beyond its cystic fibrosis franchise.",
                "category": "company",
                "datetime": 1792870140,
                "headline": "Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change."
              },
              {
                "id": 143150593,
                "url": "https://finnhub.io/api/news?id=673707359a4a72492df4a07e6cbf617ad61018a54cf7407743e17065b1091244",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1792812435,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript"
              },
              {
                "id": 143144085,
                "url": "https://finnhub.io/api/news?id=dded9140786f404630f7bf6e3ca4e57335a90cae80dfc4563ead4f419d6eb3cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm",
                "category": "company",
                "datetime": 1792810923,
                "headline": "Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III"
              },
              {
                "id": 143141725,
                "url": "https://finnhub.io/api/news?id=cf10aef4f3779a6f6eab5faf759d7610b698c4dc8a702bd883b061875ee7367a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.",
                "category": "company",
                "datetime": 1792791065,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow"
              },
              {
                "id": 143137021,
                "url": "https://finnhub.io/api/news?id=ee9914d7c012c3940106e13b79be6b379e8b83bc1f66908de6edc2f5b0d147e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots",
                "category": "company",
                "datetime": 1792786277,
                "headline": "How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs"
              },
              {
                "id": 143136366,
                "url": "https://finnhub.io/api/news?id=31de2771bdcfe4c0b02349b053147edc97577ab991ed2c57d4219a9567ec6285",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, October 23, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a",
                "category": "company",
                "datetime": 1792777320,
                "headline": "Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026"
              },
              {
                "id": 143136365,
                "url": "https://finnhub.io/api/news?id=4096afeeab360911f0fd6be6f61127974edc9434f479a10014bbe6db6d27b373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792776565,
                "headline": "Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?"
              },
              {
                "id": 143164024,
                "url": "https://finnhub.io/api/news?id=7bf434c0ccbe5ba3d62b42e7e47d658d82d5e63122da079c85b6b4b5d46e4aaf",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s",
                "category": "company",
                "datetime": 1792762993,
                "headline": "Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30"
              },
              {
                "id": 143133547,
                "url": "https://finnhub.io/api/news?id=772806fd053104a668901b32faf54bf45e0835695b33e1dc35a9d3f2fbeb914e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots",
                "category": "company",
                "datetime": 1792756851,
                "headline": "How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs"
              },
              {
                "id": 143104142,
                "url": "https://finnhub.io/api/news?id=8be9cda696951d7b2fa53e3f1851c49e66e1ca650ebc8694dae5425b54a4573d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]",
                "category": "company",
                "datetime": 1792701202,
                "headline": "Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?"
              },
              {
                "id": 143135359,
                "url": "https://finnhub.io/api/news?id=9d437d1f1011e9c7cce6e66eee3cca9850bf5b5369d42816d8af6b0029d75621",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1154326",
                "category": "company",
                "datetime": 1792671246,
                "headline": "Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s Syndrome"
              },
              {
                "id": 143099227,
                "url": "https://finnhub.io/api/news?id=2ebfb5c5ececa35f9094799bf56c6c968630fe538d74ccf06c335b846e64f665",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profilesVANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has secured the approvals, permits and land access permissions required to commence its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and L",
                "category": "company",
                "datetime": 1792670400,
                "headline": "Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project"
              },
              {
                "id": 143070139,
                "url": "https://finnhub.io/api/news?id=fd0f9110765fd8e5d5482f6bab2529f4661cb2a3525b1f8acb4178d99bca0210",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]",
                "category": "company",
                "datetime": 1792595942,
                "headline": "Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?"
              },
              {
                "id": 143087262,
                "url": "https://finnhub.io/api/news?id=eba9a293516889b9db11cf3881c5665bd9e741fb9e36f87cf455c1d1c54b430a",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "S&P 500 premarket movers on Oct. 21: SMCI, DELL, VRT, LITE, BE and HPE led gainers, while ISRG, NFLX, T, ABT and DHR led declines.",
                "category": "company",
                "datetime": 1792586166,
                "headline": "S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines"
              },
              {
                "id": 143036037,
                "url": "https://finnhub.io/api/news?id=30f63c6b342f081d573a977ff03988b6c8ab2d7237b1dd6dd44ca651ef06d703",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time",
                "category": "company",
                "datetime": 1792544172,
                "headline": "Why Should You Think About Vertex Differently Now?"
              },
              {
                "id": 143032156,
                "url": "https://finnhub.io/api/news?id=e49558c555026b92434592fdc119c2a0057ebb415679b659eb4a3f1b8bd61926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.",
                "category": "company",
                "datetime": 1792532102,
                "headline": "AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 143033121,
                "url": "https://finnhub.io/api/news?id=59314c7ab71cb22d75b313016495700c4c5d175bb0a4e388ad53dbc7407cf9d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.",
                "category": "company",
                "datetime": 1792529403,
                "headline": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know"
              },
              {
                "id": 143032238,
                "url": "https://finnhub.io/api/news?id=06f6faed4bd65e9c0e32c1aeac93309d2b2c65babcc52e7ea6d47576de38a794",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, October 20, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Fi",
                "category": "company",
                "datetime": 1792526700,
                "headline": "Vertex Appoints Daniel Brennan to its Board of Directors"
              },
              {
                "id": 142987498,
                "url": "https://finnhub.io/api/news?id=31fdc9f85d46544de5546224dd35c3aade7953f6ed84d54221601ad790c35dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...",
                "category": "company",
                "datetime": 1792336361,
                "headline": "What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders"
              },
              {
                "id": 142986224,
                "url": "https://finnhub.io/api/news?id=a17342c01986484a9cb93f40b6ab82d2decc2b5b16eba0c7b3ecd4fe51a86222",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.",
                "category": "company",
                "datetime": 1792321800,
                "headline": "Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock."
              },
              {
                "id": 142964351,
                "url": "https://finnhub.io/api/news?id=ca7f8d158feb573ae50822814442690e4de3a51cacbb99511721b68fe77fa342",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has rewarded long term shareholders, and that kind of track record naturally raises the question of whether today's valuation is still grounded in the cash the business can produce. With fresh data on its cystic fibrosis pipeline and gene therapy progress in the spotlight, investors are increasingly asking how much of that story is already priced into Vertex's cash flows. Over the past 5 years, Vertex has delivered a share price gain of 172.3%. That puts a lot of...",
                "category": "company",
                "datetime": 1792278652,
                "headline": "Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data"
              },
              {
                "id": 142963250,
                "url": "https://finnhub.io/api/news?id=d458f85fe45cebc4fcb8879f931134b5c1576acb47bc906b063a31c95c7dc32f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) stepped into the spotlight after new interim ALYFTREK data at the North American Cystic Fibrosis Conference suggested some young children regained pancreatic function and were able to stop enzyme replacement therapy. For context, Vertex Pharmaceuticals has given investors a mixed near term ride, with the 1 day share price return down 1.77% and the 30 day share price return down 2.63%, yet the 90 day share price return up 2.90% and the year to date share price...",
                "category": "company",
                "datetime": 1792264486,
                "headline": "Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In Focus"
              },
              {
                "id": 142945741,
                "url": "https://finnhub.io/api/news?id=aa2105c9129f5b1e79dd93448f96bf7795534765edd2ca26e7931a7d7caa68b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1792152004,
                "headline": "Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?"
              },
              {
                "id": 142944344,
                "url": "https://finnhub.io/api/news?id=eae8138802e1a47950740af6353ed57068f6be231a03953b3a9fa4398093b93c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1792149819,
                "headline": "1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm"
              },
              {
                "id": 142948842,
                "url": "https://finnhub.io/api/news?id=bcb654cc305cf790e80039297d36eecf57a6a4a488bec6137e1fe7fd7a648857",
                "image": "https://image.cnbcfm.com/api/v1/image/108415090-1792083266137-107344708-1701972953198-AP23320388297314.webp?v=1792083320&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.",
                "category": "company",
                "datetime": 1792142349,
                "headline": "Sickle cell gene therapies offer new hope, but access remains a major challenge"
              },
              {
                "id": 142923087,
                "url": "https://finnhub.io/api/news?id=6e35fd378e0a62ce6cc88378c605bbccbc99f8b9337b10d9e7bf2453c4481ca8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.",
                "category": "company",
                "datetime": 1792098006,
                "headline": "Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 142922371,
                "url": "https://finnhub.io/api/news?id=0e48348bc22a684c8a5a23abf82aeaab9b4850204e500088437e94878636b06e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release on July 24, 2026, that it has extended its engagement of MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 45 days, commencing Oct 19, 2026, provided that the term of the ma",
                "category": "company",
                "datetime": 1792098000,
                "headline": "Vortex Energy Corp. Announces Extension of Marketing Program"
              },
              {
                "id": 142919154,
                "url": "https://finnhub.io/api/news?id=553e59ad7b882c48cf23a174969915e627a5fd8d536b75959bd925986da895c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals is showing that it isn't a one-trick pony.",
                "category": "company",
                "datetime": 1792076460,
                "headline": "Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders"
              },
              {
                "id": 142921489,
                "url": "https://finnhub.io/api/news?id=37d2bd83656f0939b72efc73b6be3ef5abdffb99ba08e5f7de62fc4afbee0396",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals is set to report its Q3 results next month, with analysts anticipating single-digit EPS growth alongside continued earnings growth.",
                "category": "company",
                "datetime": 1792068252,
                "headline": "What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release"
              },
              {
                "id": 142881738,
                "url": "https://finnhub.io/api/news?id=72e7c9e44734b50cdef94c88faa680defd3c10cc3071502c03fa5b38fac7847a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Rising gasoline and diesel costs are pushing US inflation higher, and that puts steady cash generation and conservative balance sheets back in the spotlight. When borrowing stays expensive and prices keep climbing, investors often pay closer attention to companies that already throw off cash and carry less debt. This article breaks down three such undervalued high quality stocks and explains why they might deserve a spot on your watchlist now. The stocks highlighted below are just a small...",
                "category": "company",
                "datetime": 1791976283,
                "headline": "3 Top Quality Value Stocks To Watch In October 2026"
              },
              {
                "id": 142848728,
                "url": "https://finnhub.io/api/news?id=4ff718c0d17dfa447f9637b4c4aecc5e4e89c933ebad91449ca247f2ad041a9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.",
                "category": "company",
                "datetime": 1791895025,
                "headline": "Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142819167,
                "url": "https://finnhub.io/api/news?id=9202fe518a488cc7029f2456af0fc3ba7be6c9d583a9d1306d3305f451800fcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.",
                "category": "company",
                "datetime": 1791801063,
                "headline": "2 High-Flying Stocks on Our Watchlist and 1 We Question"
              },
              {
                "id": 142767990,
                "url": "https://finnhub.io/api/news?id=c23fb25d8e354123601b2e2720c3044259dca98eec6080b2d7c03a9f5980203d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.",
                "category": "company",
                "datetime": 1791579003,
                "headline": "Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know"
              },
              {
                "id": 142765367,
                "url": "https://finnhub.io/api/news?id=992912428f38dc107073c12c6a342e476503b1ef0a2f1fdff7eb3e860085c08d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib",
                "category": "company",
                "datetime": 1791566100,
                "headline": "Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference"
              },
              {
                "id": 142764205,
                "url": "https://finnhub.io/api/news?id=78f2a1b20a92c2f2664cbf93a4df03d907ffde640be59eabf97e4f652329c59c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.",
                "category": "company",
                "datetime": 1791560209,
                "headline": "Is Vertex Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142791249,
                "url": "https://finnhub.io/api/news?id=ce130766d00aa1c08d2a1df20fc7bd34f115e6fe5d4865d156ff6c101c615623",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented -Vertex",
                "category": "company",
                "datetime": 1791551850,
                "headline": "Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis"
              },
              {
                "id": 142791250,
                "url": "https://finnhub.io/api/news?id=3d3e37c3f06a870cbec31c0f6d53233afd5f5565019bba624ae01b7aa75b6011",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1791541816,
                "headline": "If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 142764929,
                "url": "https://finnhub.io/api/news?id=be680a565332fc5f7ae8ac268fd4c925ad8cd9d4784cc24b509d7d120a2a1540",
                "image": "https://image.cnbcfm.com/api/v1/image/108376811-1791466603254-f527cd41-e1f4-4eb3-9865-63a2ba75f085.jpg?v=1791466673&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "For the final 10% of cystic fibrosis patients who cannot benefit from breakthrough drugs, Emily's Entourage is funding research to find treatments.",
                "category": "company",
                "datetime": 1791529201,
                "headline": "For the final 10% of cystic fibrosis patients, the breakthrough still hasn't come"
              },
              {
                "id": 142730997,
                "url": "https://finnhub.io/api/news?id=432e0925ebab3aeb2ff78568017b127382217a73fb75460d7f75b5111e5a2c09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications.",
                "category": "company",
                "datetime": 1791480540,
                "headline": "Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition"
              },
              {
                "id": 142729942,
                "url": "https://finnhub.io/api/news?id=e6f46e10b531fadf9511813c96e130f8dcb6ef08c2be2d1a0d6dc481a193f9a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher interest rates, and persistent inflation created headwinds for equities and bonds, although strong corporate earnings and continued AI investment helped support […]",
                "category": "company",
                "datetime": 1791467998,
                "headline": "Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why"
              },
              {
                "id": 142762432,
                "url": "https://finnhub.io/api/news?id=cb41862f1e2653e356536ac1c78b5786d53ca2c35c8a4c0ba89ccceab1a9f0fb",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.",
                "category": "company",
                "datetime": 1791454303,
                "headline": "RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576"
              },
              {
                "id": 142700467,
                "url": "https://finnhub.io/api/news?id=171419e8f3d4371fa9aeba7aff9191a02d227a86a40539d8b98c67c7d01a1ee7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, October 07, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.\"",
                "category": "company",
                "datetime": 1791403200,
                "headline": "Vertex to Announce Third Quarter 2026 Financial Results November 2nd"
              },
              {
                "id": 142688595,
                "url": "https://finnhub.io/api/news?id=850cee1d2d2199d33e784edd409b737c35f19becfe776b1cac3049376df916ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and still trade as if they are largely overlooked. This article breaks down three such high quality but ignored US stocks from our screener and explains why they may warrant a closer look. The three stocks covered below are just a starting sample, since the full...",
                "category": "company",
                "datetime": 1791365064,
                "headline": "NVIDIA And 2 Elite Undervalued Stocks To Own"
              },
              {
                "id": 142652471,
                "url": "https://finnhub.io/api/news?id=64e8feaa5bebd866362af05857dd3615e6f456997b2380633ef07012abc6d3a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1791267180,
                "headline": "Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?"
              },
              {
                "id": 142662618,
                "url": "https://finnhub.io/api/news?id=d78ffd39021735e4739cfbbd4e7ce2c89bcdbad94ff4f003fc44637d8d221831",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/Nasdaq-Inscription-Next-To-Us-Dollars--T.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.",
                "category": "company",
                "datetime": 1791212429,
                "headline": "Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average"
              },
              {
                "id": 142635190,
                "url": "https://finnhub.io/api/news?id=1796d84c2e8a9f60a1a7b9d29266b5788128dd7ef6544af57255d46a92509159",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1791201607,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142635191,
                "url": "https://finnhub.io/api/news?id=943cb8c1f83470d9cc644feb430e61cb7adee87a478c61044c0106a7f544aae2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potentialVANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons Ri",
                "category": "company",
                "datetime": 1791201600,
                "headline": "Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project"
              },
              {
                "id": 142632186,
                "url": "https://finnhub.io/api/news?id=e577f7a9f57d44c3b91d86f0a9d89c225339a9fd4ab39a07dabc04048da37e08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
                "category": "company",
                "datetime": 1791194100,
                "headline": "2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down"
              },
              {
                "id": 142624185,
                "url": "https://finnhub.io/api/news?id=773d3787e684fba498bba3b49094c209329c0e46fcca5973e7c495eb6d0c1b89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.",
                "category": "company",
                "datetime": 1791124497,
                "headline": "Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142600044,
                "url": "https://finnhub.io/api/news?id=1510dab33932c078bbdfa82bd31981132c1fe6efe647aba58030c1ffd02f120c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]",
                "category": "company",
                "datetime": 1790995209,
                "headline": "Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets"
              },
              {
                "id": 142563799,
                "url": "https://finnhub.io/api/news?id=33db27cdedbadf5d64a8a23a56996eefb15a99869c55975888b7930bc6d25e12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...",
                "category": "company",
                "datetime": 1790892442,
                "headline": "Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks"
              },
              {
                "id": 142563800,
                "url": "https://finnhub.io/api/news?id=f4e27e824ed2216180d2fc1ff43a6009ba5e9ba7b333adb15c9fd852d617ac38",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.",
                "category": "company",
                "datetime": 1790888406,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know"
              },
              {
                "id": 142562962,
                "url": "https://finnhub.io/api/news?id=8b2cc6a116d127762d8c7ff932bc5889f16d9ceca2d269093a071a3cf8886285",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (\"Vortex\" or the \"Company\") is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the \"Meadows Project\"). The Meadows Project is represented by Saskatchewan Subsur",
                "category": "company",
                "datetime": 1790888400,
                "headline": "Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan"
              },
              {
                "id": 142562009,
                "url": "https://finnhub.io/api/news?id=efdd7ae1fb5005fdb07db2a037384ba09bae20b4b50dc26ed3c05ad7df9cd2ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.",
                "category": "company",
                "datetime": 1790882255,
                "headline": "Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142540765,
                "url": "https://finnhub.io/api/news?id=7d6465b472d118677c03014527a5f47cd568772afebdfde05f26b16e70df37cb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440523601/image_1440523601.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.",
                "category": "company",
                "datetime": 1790825460,
                "headline": "The Top HealthTech Questions Landing On Our Desks"
              },
              {
                "id": 142520017,
                "url": "https://finnhub.io/api/news?id=645e00c63c078d5113e0f74e41cc2998e00ddd331b98c15a9aba17eb591b050c",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1790698533,
                "headline": "$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 142517094,
                "url": "https://finnhub.io/api/news?id=cb1f42ba0619a23b4870af3deeed19596359754d26553e137f4f5b0e7ce4a583",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1790688914,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142488937,
                "url": "https://finnhub.io/api/news?id=77a4693c64636b6f902d7874bb26412235939b809c4b9d7c878e6e5d6afd88e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This biotech player is firing on all cylinders.",
                "category": "company",
                "datetime": 1790674200,
                "headline": "2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right."
              },
              {
                "id": 142495235,
                "url": "https://finnhub.io/api/news?id=159fbb2c029dd797d2b9e77c1bf78c3fe5e3de6e5840d79f57d72604817f8792",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/178368474/image_178368474.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals commands a dominant, highly profitable cystic fibrosis franchise. Find out why VRTX stock is downgraded to a hold.",
                "category": "company",
                "datetime": 1790670621,
                "headline": "Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade"
              },
              {
                "id": 142493778,
                "url": "https://finnhub.io/api/news?id=0b2f7f810f70395a2cacb2e0d08118903ac1ac743984c1905bf6998b3ab15787",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237482641/image_2237482641.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.",
                "category": "company",
                "datetime": 1790667020,
                "headline": "Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress"
              },
              {
                "id": 142474021,
                "url": "https://finnhub.io/api/news?id=53f4be2f0dd2ed26d97af2ff1e281be817a054b406c7bd3b609affe35a6362ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]",
                "category": "company",
                "datetime": 1790642228,
                "headline": "Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?"
              },
              {
                "id": 142495491,
                "url": "https://finnhub.io/api/news?id=93f4cbe113b07d716821f1fd4548930b4da186454498b35f96b848e003e63541",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Grid-Delays-Stall-Data-Centers.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.",
                "category": "company",
                "datetime": 1790606813,
                "headline": "Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday"
              },
              {
                "id": 142496737,
                "url": "https://finnhub.io/api/news?id=2d4021a8657172a482a3f220c240c24bbceff45d44e7e6f1f0f12be23a652488",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "UBS  analyst Michael Yee   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.",
                "category": "company",
                "datetime": 1790604049,
                "headline": "UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615"
              },
              {
                "id": 142463805,
                "url": "https://finnhub.io/api/news?id=755d2c372c9a61d3c7e7d4171d959a6953d7d8fb9e6d1302ea12d1028db6c15a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 46.9% over the past six months, topping the S&P 500 by 25.5 percentage points.",
                "category": "company",
                "datetime": 1790591916,
                "headline": "2 Healthcare Stocks to Target This Week and 1 We Avoid"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 75,
            "discarded_article_count": 57
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.4,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "靠近20日高位；升放量(近10日6日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 1193410,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 1459260,
              "avg_vol_20": 1248970,
              "avg_vol_30": 1193410,
              "range_pct_10": 0.1031226800941255,
              "range_pct_20": 0.1031226800941255,
              "range_pct_30": 0.1031226800941255,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 6,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.222765017889912,
              "dist_to_20d_high": 0.031200555958423856,
              "down_shrink_days": 2,
              "breakout_level_20d": 537.81,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 1
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.8275721513164456,
              "turnoverUsdM": 531.19532486579,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 491.565,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.7,
            "take_profit_price": 555.5532,
            "target_multiplier": 1.9,
            "technical_strength": 1.85,
            "take_profit_percent": 6.6
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.655144302632891,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 14.7325,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.83
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 55.8
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1021
    },
    "kdj": {
      "d": 68.86,
      "j": 64.09,
      "k": 67.27,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.07
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 11326010,
      "recentSlope": 546591,
      "previousSlope": -307480
    },
    "rsi": 56.24,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 495.1657,
      "position": "SAR喺價下",
      "distancePct": 4.96,
      "previousTrend": "上升"
    },
    "ma50": 523.0532,
    "macd": {
      "macd": 1.3412813870037326,
      "trend": "強烈看漲",
      "signal": -1.2893255406381257,
      "histogram": 2.630606927641858
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 510.2285,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 6
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.81,
      "score": 4,
      "avgVolume": 1265506,
      "currentVolume": 1019510
    },
    "derived": {
      "ma20": 509.8505,
      "ma50": 523.0532,
      "prevClose": 517.49,
      "avgVolume10": 1442481,
      "avgVolume20": 1265506,
      "changePercent": 0.68,
      "avgVolumeForScore": 1265506
    },
    "ma_cross": {
      "ma20": 509.8505,
      "ma50": 523.0532,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 510.1355,
      "prevMa50": 522.9436,
      "spreadPct": 2.52,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 487.3439,
      "upper": 532.3571,
      "position": "上半部"
    },
    "rsi_short": 67.52,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.81
    }
  }
}

Raw metrics JSON

 
{
  "close": 521.03,
  "volume": 1019510,
  "changePercent": 0.68
}

Scores are derived from cached daily market data using the Solorank 110-point standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.